Short description
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Description
Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world.
Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
Last funding
No Way
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Suzhou, Jiangsu, China, Asia
Founded on
August 1, 2011
Exited on
October 24, 2018
Went public on
October 24, 2018
Stock symbol
1801
Non-profit?
No
Acquired?
No
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccess, Blurry Noaccess, Blurry Noaccess, Nopepepe, No Way, Blurry Noaccess, Absolutely Noaccess, No Way, Noaccess, Noaccess, Uh Ohhhh, Nopepepe, Nopepepe, Nopepepe, Nopepepe, Uh Ohhhh, Noway Youcantaccess
Sign in for full access
Founders
Michael Yu, Wei Li
Funding rounds count
1
Portfolio organisations count
Noaccessforu, Cannot Access
Sign in for full access
Exits count
Noway Youcantaccess, Blurry Noaccess
Sign in for full access
IPO exits count
1